Notice Number: NOT-AR-14-009
Key Dates
Release Date: May 10, 2013
RFA-AR-14-004
Issued by
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Purpose
This Notice is to inform potential applicants that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is revising the Award Budget section of RFA-AR-14-004 "Biomarker Candidate Platforms for Inflammatory Diseases (U44)" as follows:
Part 2. Section II. Award Information
Award Budget
CURRENT LANGUAGE:
Budgets up to $225,000 total costs per year for Phase I and up to $1,500,000 total costs per year for Phase II may be requested.
MODIFIED LANGUAGE:
According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, NIAMS will allow awards to exceed these amounts by up to 50% ($225,000 for Phase I and $1,500,000 for Phase II).
Applicants are strongly encouragedto contact NIH program officials prior to submitting any application in excess of the guidelines. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
All other aspects of the FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Ricardo R. Cibotti, Ph.D., Program Director
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Telephone: 301-451-5888
Email: [email protected]
and Human Services (HHS)
